Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Alzheimer's disease is characterized in part by abnormal deposits in the brain of the peptide beta amyloid (Abeta), in the form of plaques. Recent work with a transgenic model of Abeta deposition has uncovered a remarkable capacity of antibodies to prevent or clear these deposits. These experiments offer the attractive possibility, albeit some way in the future, of using antibodies as a therapy in Alzheimer's disease.


Journal article


Trends Pharmacol Sci

Publication Date





2 - 3


Alzheimer Disease, Amyloid beta-Peptides, Animals, Humans, Immunization, Mice, Mice, Transgenic, Peptide Fragments